Trial IRCT20200317046797N4
Publication Ansarin K, BioImpacts (2020) (published paper)
Dates: 2020-04-18 to 2020-05-19
Funding: Public/non profit (Tabriz University of Medical Sciences)
Conflict of interest: No
Methods | |
RCT Blinding: Unblinded | |
Location :
Single center / Iran Follow-up duration (days): 28 | |
Inclusion criteria |
|
Exclusion criteria |
|
Interventions | |
Treatment
Bromhexine 8 mg orally 3 times a day for 2 weeks |
|
Control
Standard care | |
Participants | |
Randomized participants : Bromhexine=39 Standard care=39 | |
Characteristics of participants N= 78 Mean age : NR 43 males Severity : Mild: n=0 / Moderate: n=* / Severe: n=* Critical: n=* Number of vaccinated participants: NR | |
Primary outcome | |
In the register Hospitalization days, Need for mechanical ventilation, Condition of discharge (death or recovery), Period of mechanical ventilation | |
In the report Improvement in the rate of ICU admissions, intubation/mechanical ventilation, and 28-days mortality. | |
Documents available |
Protocol NR Statistical plan NR Data-sharing willing stated in the publication: Not reported |
Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Some concerns |
General comment |
In addition to the published article, the trial registry was used in data extraction and assessment of risk of bias.
Both groups received standard therapy based on the Iranian national COVID-19 treatment protocol and best practice guidelines at that time and also the “Hydroxychloroquine 200 mg/d for two weeks” in addition to supportive and symptomatic therapy. The registry's primary outcomes did not reflect the reported primary outcomes. Some outcomes from the registry were not reported in the paper (e.g., period of mechanical ventilation). Secondary outcomes (e.g., number of patients with specific symptoms) were reported in the paper, but were not pre-specified in the trial registry. Target sample size specified in the registry was achieved. There was no change from the trial registration in the intervention and control treatments. |